ACRS – Aclaris Therapeutics Inc
Aclaris Therapeutics, Inc.ACRS
$1.14Name : Aclaris Therapeutics, Inc.
Sector : Healthcare
Industry: Diagnostics & Research
Mark. Cap: $123,288,720.00
EPSttm : -1.71
Aclaris Therapeutics, Inc.
$1.14
0.88%$0.01Float Short %
6.81
Margin Of Safety %
Put/Call OI Ratio
0.34
EPS Next Q Diff
-0.05
EPS Last/This Y
1.1
EPS This/Next Y
-0.15
Price
1.14
Target Price
7.75
Analyst Recom
1.4
Performance Q
-54.58
Relative Volume
0.75
Beta
0.57
Ticker: ACRS
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-03-20 | ACRS | 1.585 | 0.08 | 0.00 | 1637 |
| 2025-03-21 | ACRS | 1.6 | 0.08 | 0.00 | 1626 |
| 2025-03-24 | ACRS | 1.66 | 0.08 | 0.42 | 1553 |
| 2025-03-25 | ACRS | 1.675 | 0.09 | 0.00 | 1641 |
| 2025-03-26 | ACRS | 1.61 | 0.09 | 55.50 | 1642 |
| 2025-03-27 | ACRS | 1.61 | 0.09 | 55.50 | 1642 |
| 2025-03-28 | ACRS | 1.59 | 0.24 | 0.00 | 1857 |
| 2025-03-31 | ACRS | 1.525 | 0.23 | 32.00 | 1899 |
| 2025-04-01 | ACRS | 1.485 | 0.25 | 90.00 | 1931 |
| 2025-04-02 | ACRS | 1.54 | 0.31 | 8.18 | 2021 |
| 2025-04-03 | ACRS | 1.495 | 0.34 | 999.99 | 2060 |
| 2025-04-04 | ACRS | 1.39 | 0.36 | 0.00 | 2090 |
| 2025-04-07 | ACRS | 1.325 | 0.36 | 0.00 | 2095 |
| 2025-04-08 | ACRS | 1.22 | 0.36 | 0.00 | 2096 |
| 2025-04-09 | ACRS | 1.21 | 0.36 | 66.00 | 2098 |
| 2025-04-10 | ACRS | 1.07 | 0.44 | 5.00 | 2226 |
| 2025-04-11 | ACRS | 1.145 | 0.40 | 53.00 | 2159 |
| 2025-04-14 | ACRS | 1.17 | 0.36 | 0.00 | 2107 |
| 2025-04-15 | ACRS | 1.11 | 0.36 | 0.00 | 2107 |
| 2025-04-16 | ACRS | 1.125 | 0.36 | 0.00 | 2137 |
| 2025-04-17 | ACRS | 1.135 | 0.34 | 0.00 | 2196 |
| 2025-04-18 | ACRS | 1.14 | 0.34 | 0.00 | 2196 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-03-20 | ACRS | 1.57 | 43.8 | - | -0.60 |
| 2025-03-21 | ACRS | 1.60 | 43.8 | - | -0.61 |
| 2025-03-24 | ACRS | 1.70 | 50.0 | - | -0.61 |
| 2025-03-25 | ACRS | 1.67 | 50.0 | - | -0.61 |
| 2025-03-26 | ACRS | 1.62 | 50.0 | - | -0.61 |
| 2025-03-27 | ACRS | 1.61 | 50.0 | - | -0.61 |
| 2025-03-28 | ACRS | 1.59 | 50.0 | - | -0.61 |
| 2025-03-31 | ACRS | 1.53 | 50.0 | - | -0.61 |
| 2025-04-01 | ACRS | 1.48 | 50.0 | - | -0.61 |
| 2025-04-02 | ACRS | 1.54 | 50.0 | - | -0.61 |
| 2025-04-03 | ACRS | 1.49 | 50.0 | - | -0.61 |
| 2025-04-04 | ACRS | 1.39 | 50.0 | - | -0.61 |
| 2025-04-07 | ACRS | 1.32 | 50.0 | - | -0.61 |
| 2025-04-08 | ACRS | 1.23 | 50.0 | - | -0.61 |
| 2025-04-09 | ACRS | 1.21 | 50.0 | - | -0.61 |
| 2025-04-10 | ACRS | 1.08 | 50.0 | - | -0.61 |
| 2025-04-11 | ACRS | 1.15 | 50.0 | - | -0.61 |
| 2025-04-14 | ACRS | 1.18 | 50.0 | - | -0.61 |
| 2025-04-15 | ACRS | 1.12 | 50.0 | - | -0.61 |
| 2025-04-16 | ACRS | 1.12 | 50.0 | - | -0.61 |
| 2025-04-17 | ACRS | 1.14 | 50.0 | - | -0.61 |
| 2025-04-18 | ACRS | 1.14 | 50.0 | - | -0.61 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-03-20 | ACRS | 4.20 | 278.15 | 5.22 |
| 2025-03-21 | ACRS | 4.20 | 278.15 | 5.22 |
| 2025-03-24 | ACRS | 4.20 | 278.15 | 5.22 |
| 2025-03-25 | ACRS | 4.20 | 278.15 | 5.22 |
| 2025-03-26 | ACRS | 4.20 | 278.15 | 6.60 |
| 2025-03-27 | ACRS | 4.20 | 278.15 | 6.60 |
| 2025-03-28 | ACRS | 4.20 | 278.15 | 6.60 |
| 2025-03-31 | ACRS | 4.20 | 277.98 | 6.60 |
| 2025-04-01 | ACRS | 4.20 | 277.98 | 6.60 |
| 2025-04-02 | ACRS | 4.20 | 277.98 | 6.60 |
| 2025-04-03 | ACRS | 4.20 | 277.98 | 6.60 |
| 2025-04-04 | ACRS | 4.20 | 277.98 | 6.60 |
| 2025-04-07 | ACRS | 4.20 | 278.07 | 6.60 |
| 2025-04-08 | ACRS | 4.20 | 278.07 | 6.60 |
| 2025-04-09 | ACRS | 4.20 | 278.07 | 6.60 |
| 2025-04-10 | ACRS | 4.20 | 278.07 | 6.83 |
| 2025-04-11 | ACRS | 4.20 | 278.07 | 6.83 |
| 2025-04-14 | ACRS | 4.20 | 278.07 | 6.83 |
| 2025-04-15 | ACRS | 4.20 | 278.07 | 6.83 |
| 2025-04-16 | ACRS | 4.20 | 278.07 | 6.83 |
| 2025-04-17 | ACRS | 4.18 | 278.07 | 6.81 |
| 2025-04-18 | ACRS | 4.18 | 278.07 | 6.81 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.1
Avg. EPS Est. Current Quarter
-0.12
Avg. EPS Est. Next Quarter
-0.15
Insider Transactions
4.18
Institutional Transactions
278.07
Beta
0.57
Average Sales Estimate Current Quarter
4
Average Sales Estimate Next Quarter
3
Fair Value
Quality Score
26
Growth Score
34
Sentiment Score
36
Actual DrawDown %
96.3
Max Drawdown 5-Year %
-97.8
Target Price
7.75
P/E
Forward P/E
PEG
P/S
6.59
P/B
0.79
P/Free Cash Flow
EPS
-1.51
Average EPS Est. Cur. Y
-0.61
EPS Next Y. (Est.)
-0.76
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-705.44
Relative Volume
0.75
Return on Equity vs Sector %
-104.9
Return on Equity vs Industry %
-95.6
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.04
EBIT Estimation
Aclaris Therapeutics, Inc.Sector: Healthcare
Industry: Diagnostics & Research
Employees: 61
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its Contract Research segment provides laboratory services. The company also develops ATI-1777, a soft JAK 1/3 inhibitor in Phase 2b trial for the treatment of atopic dermatitis and other dermatologic conditions; Bosakitug (ATI-045), an anti-TSLP monoclonal antibody in Phase 2a trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; Zunsemetinib (ATI-450), a mitogen-activated protein kinase-activated protein kinase 2 inhibitor under Phase 1b/2 trials for the treatment of metastatic breast cancer and pancreatic ductal adenocarcinoma; and ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in preclinical stage to treat various atopic, immunologic, and respiratory diseases, as well as an ITK selective inhibitor candidate for the treatment of autoimmune diseases. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
stock quote shares ACRS – Aclaris Therapeutics Inc Stock Price stock today
news today ACRS – Aclaris Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch ACRS – Aclaris Therapeutics Inc yahoo finance google finance
stock history ACRS – Aclaris Therapeutics Inc invest stock market
stock prices ACRS premarket after hours
ticker ACRS fair value insiders trading